Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
*[[Adult T-cell leukemia-lymphoma]] | *[[Adult T-cell leukemia-lymphoma]] | ||
| + | *[[Anaplastic glioma]] | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
| Line 41: | Line 42: | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
| − | |||
*[[Unknown primary]] | *[[Unknown primary]] | ||
</div> | </div> | ||
| Line 131: | Line 131: | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:Adult T-cell leukemia-lymphoma medications]] | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
| + | [[Category:Anaplastic glioma medications]] | ||
[[Category:Anaplastic large cell lymphoma medications]] | [[Category:Anaplastic large cell lymphoma medications]] | ||
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| Line 162: | Line 163: | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] | ||
| − | |||
[[Category:Drugs FDA approved in 1983]] | [[Category:Drugs FDA approved in 1983]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 02:37, 21 January 2018
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing's sarcoma
- Extranodal NK/T-cell lymphoma, nasal type
- Follicular lymphoma
- Hemophagocytic lymphohistiocytosis
- Hepatobiliary cancer
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Langerhans cell histiocytosis
- Low-grade glioma
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- NK/T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Soft tissue sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
- Unknown primary
Patient drug information
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/10/1983: Initial FDA approval for refractory testicular tumors
Also known as
- Code names: VP-16, VP-TEC, VP 16213
- Generic name: etoposide phosphate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Aside | Beposid | Bioposide | Celltop | Citodox | Epocin | Eposid | Eposide |
| Eposido | Eposin | Epsidox | ETO | Etocris | Etomedac | Etonolver | Etopofos |
| Etopophos | Etopos | Etoposid | Etoposido | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | Labimion | Lastet | Lastet S |
| Neoplaxol | Nexvep | Onkoposid | Optasid | Percas | Posid | Posidon | Posyd |
| Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid | Tosuben | Vepefos |
| Vepeside | Vepsid | Vepside | |||||
References
Categories:
- Drug index
- Intravenous medications
- Oral medications
- Irritant chemotherapy
- Topoisomerase inhibitors
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing's sarcoma medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Hemophagocytic lymphohistiocytosis medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Langerhans cell histiocytosis medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Drugs FDA approved in 1983
- WHO Essential Cancer Medicine